Arcturus Therapeutics (NASDAQ:ARCT) Issues Quarterly Earnings Results, Beats Expectations By $0.16 EPS

Arcturus Therapeutics (NASDAQ:ARCT) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.16, FiscalAI reports. The company had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.11 million. Arcturus Therapeutics had a negative return on equity of 44.42% and a negative net margin of 317.62%.

Here are the key takeaways from Arcturus Therapeutics’ conference call:

• ARCT-810 completed Phase II enrollment and dosing in OTC deficiency, with U.S. and European data expected in Q3 2026 alongside FDA-requested supplementary data and an update on the regulatory path for adult and pediatric development.
• ARCT-032’s Phase II cystic fibrosis study remains on schedule, supported by expanded enrollment in Israel and Turkey; Arcturus expects to decide whether to advance to Phase III in Q4 2026, which would trigger substantial manufacturing and development support from Thermo Fisher.
• Arcturus regained global rights to KOSTAIVE and its broader self-amplifying mRNA vaccine portfolio after ending the CSL Seqirus collaboration. The settlement included a $12 million cash payment and release from approximately $16 million in liabilities, while returning strategic control that could enable commercialization and new partnerships.
• Revenue fell sharply to $3 million in Q2 2026 from $28.3 million a year earlier as the CSL collaboration wound down, while cash declined to $191.5 million from $230.8 million at year-end 2025.
• Management said the company has more than two and a half years of cash runway through year-end 2028, but it will need to balance rare-disease clinical spending with efforts to commercialize or partner the returned vaccine assets.

Arcturus Therapeutics Stock Performance

Shares of ARCT opened at $7.41 on Friday. Arcturus Therapeutics has a one year low of $5.50 and a one year high of $24.17. The stock has a 50-day moving average price of $6.77 and a 200 day moving average price of $7.38. The company has a market capitalization of $210.59 million, a P/E ratio of -2.24 and a beta of 2.39.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ARCT shares. Wall Street Zen lowered Arcturus Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Arcturus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $24.25.

Hedge Funds Weigh In On Arcturus Therapeutics

Institutional investors have recently made changes to their positions in the business. Osaic Holdings Inc. grew its position in shares of Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after buying an additional 738 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Arcturus Therapeutics by 163.4% in the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 2,586 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in Arcturus Therapeutics during the 4th quarter valued at $64,000. Intech Investment Management LLC bought a new position in Arcturus Therapeutics during the 4th quarter valued at $70,000. Finally, CANADA LIFE ASSURANCE Co grew its holdings in Arcturus Therapeutics by 65.1% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 4,737 shares in the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.